TIDMGEN
Company Announcement
COPENHAGEN, Denmark; July 01, 2021 --
https://www.globenewswire.com/Tracker?data=xLuy3WDxhyt_VRI6D_8mVLGEh-MEOzD_M7xnyqWp8BhnyO8778pSCS3AkV87EzmrxEWYecwt2WThqnbvVRNp3g==
Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program
has been completed on June 30, 2021.
On February 23, 2021 Genmab announced the initiation of a share
buy-back program to mitigate dilution from warrant exercises and to
honor our commitments under our Restricted Stock Units program.
The share buy-back program was expected to be completed no later
than June 30, 2021 and comprised up to 200,000 shares.
The following transactions were executed under the program from
June 28, 2021, to June 30, 2021:
Average price
No. of shares (DKK) Total value (DKK)
------------------------- ------------- ----------------- -----------------
Accumulated through last
announcement 193,400 429,072,364
June 28, 2021 3,000 2,609.07 7,827,210
June 29, 2021 2,000 2,601.09 5,202,180
June 30, 2021 1,600 2,580.80 4,129,280
Total 6,600 17,158,670
------------------------- ------------- ----------------- -----------------
Accumulated under the
program 200,000 446,231,034
Details of each transaction are included as an appendix to this
announcement.
Genmab's accumulated share buy-back from 24 February 2021 to 30
June, 2021 amounts to 200,000 shares at a total cost of DKK 446.23
million. The announced share buy-back program has thus been
completed.
Following these transactions, Genmab holds 299,206 shares as
treasury shares, corresponding to 0.46% of the total share capital
and voting rights.
The share buy-back program was undertaken in accordance with
Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated
Regulation (EU) 2016/1052, also referred to as the "Safe Harbour
Regulation." Further details on the terms of the share buy-back
program can be found in our company announcement no. 11 dated
February 23, 2021.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of patients with cancer. Founded in
1999, Genmab is the creator of multiple approved antibody
therapeutics that are marketed by its partners. The company aims to
create, develop and commercialize differentiated therapies by
leveraging next-generation antibody technologies, expertise in
antibody biology, translational research and data sciences and
strategic partnerships. To create novel therapies, Genmab utilizes
its next-generation antibody technologies, which are the result of
its collaborative company culture and a deep passion for
innovation. Genmab's proprietary pipeline consists of modified
antibody candidates, including bispecific T-cell engagers and
next-generation immune checkpoint modulators, effector function
enhanced antibodies and antibody-drug conjugates. The company is
headquartered in Copenhagen, Denmark with locations in Utrecht, the
Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more
information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=xLuy3WDxhyt_VRI6D_8mVIIHZ3jHPqXL2WuOyi4L2ubVzIcaMgcAnhJyM6xyb3X-MiEszJXpXNiDf4eB-bKxiQ==
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=E-2SKXordBrJgA0nXcXD6lQ8RcBcEEqJCncMl-cvZ3qOHjRndiT0qHVletc-UJ7LWLElHd37CL4ZXuG4T7ppkA==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=TuxY5n4ep6-aFIKgNHkXpr1rfNXn5JRlA_vBVyCOlNIwWAhH6e0rTaC1adpVZ9P1kiusjurkWIJfbLh-73a7ww==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=n_oUAG5IxzaMM9o7aI7NrzNdmQLnhpSxvwH7_ee9ABNWrGhx0rbNeaJimYhzIz67243INsPkQX8qzHHa9W3fQQ==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=n_oUAG5IxzaMM9o7aI7Nr25J3eK6qkC5kSYaGIf8hlnZZm8qqvGsWGP5vmsqKAS0Hhd8bTOrSAP6W_UF0anEciODDxGaX6B0p2Hf7_kACnY=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 56
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachments
-- 210701_CA56_Completion of share buy-back program
https://ml-eu.globenewswire.com/Resource/Download/7cf3a588-5282-4829-9143-9c81288240d9
-- 210701_CA56_Appendix_Specification for June 28-30
https://ml-eu.globenewswire.com/Resource/Download/8ccf556a-a27e-4e2b-bcba-f9fe159124c7
(END) Dow Jones Newswires
July 01, 2021 03:42 ET (07:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2023 to Mar 2024